A 3-year-old child in rural India presents with acute bacterial meningitis. CSF culture grows Streptococcus pneumoniae. The organism is resistant to penicillin (MIC 2 μg/mL) and cephalosporin MIC is 1 μg/mL. What is the drug of choice for meningitis in this case?

Explanation

## Management of Penicillin-Resistant S. pneumoniae Meningitis ### Resistance Profile & Clinical Significance **Key Point:** This isolate shows **penicillin resistance** (MIC 2 μg/mL; susceptible ≤0.06) and **reduced cephalosporin susceptibility** (MIC 1 μg/mL). In meningitis, even "intermediate" cephalosporin resistance (MIC 0.5–1 μg/mL) is clinically significant because CNS penetration is limited and CSF concentrations may be subtherapeutic. ### Why Combination Therapy Is Mandatory **High-Yield:** The standard of care for penicillin-resistant S. pneumoniae meningitis is **vancomycin + high-dose cephalosporin (cefotaxime or ceftriaxone)**. 1. **Vancomycin** achieves adequate CSF penetration (especially with inflamed meninges) and is active against penicillin-resistant strains. 2. **High-dose cefotaxime** (2 g IV every 4–6 hours) provides synergy and covers the organism despite reduced susceptibility. 3. **Combination approach** ensures bactericidal activity and reduces risk of treatment failure. ### Dosing Regimen for Meningitis | Drug | Dose (Meningitis) | CSF Penetration | Notes | |------|-------------------|-----------------|-------| | **Vancomycin** | 15–20 mg/kg IV every 8–12 hrs | 10–20% (inflamed meninges) | Monitor trough levels (15–20 μg/mL) | | **Cefotaxime** | 2 g IV every 4–6 hrs (high-dose) | 5–10% (inflamed meninges) | Synergistic with vancomycin | | **Ceftriaxone** | 2 g IV every 12 hrs (alternative) | 5–10% (inflamed meninges) | Equivalent to cefotaxime | **Clinical Pearl:** Dexamethasone (0.15 mg/kg IV every 6 hrs for 4 days) is given concurrently to reduce meningeal inflammation and improve antibiotic penetration. ### Why Each Alternative Fails **Cefotaxime monotherapy** (option 0): - MIC of 1 μg/mL is at the upper limit of intermediate resistance - CSF penetration is only 5–10% even with high-dose IV therapy - Monotherapy risks inadequate CSF concentrations and clinical failure - Must be combined with vancomycin **Chloramphenicol** (option 1): - Excellent CSF penetration (60–80%) - However, it is **bacteriostatic**, not bactericidal—inadequate for meningitis - Rarely used in modern practice; reserved only for penicillin-anaphylactic patients when vancomycin is unavailable - Not first-line for any meningitis in current guidelines **Meropenem** (option 3): - Carbapenem with good CSF penetration - Can be used as an alternative in penicillin-anaphylactic patients - However, not superior to vancomycin + cephalosporin combination - Not standard first-line for pneumococcal meningitis ### Treatment Algorithm ```mermaid flowchart TD A[S. pneumoniae meningitis]:::outcome --> B{Penicillin susceptibility?}:::decision B -->|Susceptible| C[Cefotaxime or Ceftriaxone alone]:::action B -->|Resistant| D[Vancomycin + Cefotaxime]:::action D --> E[Add dexamethasone]:::action E --> F[Monitor CSF sterilization & clinical response]:::outcome ``` **Mnemonic:** **VCR** = **V**ancomycin + **C**ephalosporin + **R**esistant pneumococcus meningitis. **Warning:** Do not use monotherapy with any single agent for resistant pneumococcal meningitis. Combination therapy is evidence-based and reduces mortality. [cite:Harrison 21e Ch 297; Park 26e Ch 3]